Experiences of melt fi ll production of Fenretinide/Lym-X-Sorb™ hard gelatin capsules for Phase I clinical trial

Elliott, M.A. and Prasad, E. and Ford, S.J. and Halbert, G.W. (2010) Experiences of melt fi ll production of Fenretinide/Lym-X-Sorb™ hard gelatin capsules for Phase I clinical trial. In: UK-PharmSci 2010 – The Science of Medicines, 2010-09-01 - 2010-09-03.

[thumbnail of Elliot-etal-PharmSci-2010-Experiences-of-melt-fi-ll-production-of-Fenretinide-Lym-X-Sorb-hard-gelatin-capsules]
Preview
Text. Filename: Elliot_etal_PharmSci_2010_Experiences_of_melt_fi_ll_production_of_Fenretinide_Lym_X_Sorb_hard_gelatin_capsules.pdf
Download (218kB)| Preview

    Abstract

    Fenretinide is a pro-apoptotic, cytotoxic, synthetic Vitamin A analogue with application in the treatment of Ewing’s sarcoma. For pediatric study, a ‘cookie dough’ formulation had been developed, improving upon an existing corn oil formulation. We report on a simplified capsular formulation of Fenretinide with the novel solubility and bioavailability enhancing lipid matrix, Lym-X-Sorb™.

    ORCID iDs

    Elliott, M.A. ORCID logoORCID: https://orcid.org/0000-0002-9964-5671, Prasad, E. ORCID logoORCID: https://orcid.org/0000-0002-5412-9374, Ford, S.J. and Halbert, G.W.;